Latest news with #VMS
Associated Press
3 days ago
- Business
- Associated Press
Canstar Strengthens Technical Advisory Board with the Appointment of Geologist and VMS Mineralization Expert, Dr. Stephen J. Piercey, P.Geo., FGC
Toronto, Ontario--(Newsfile Corp. - June 18, 2025) - Canstar Resources Inc. (TSXV: ROX) (OTC Pink: CSRNF) ('Canstar or the 'Company') has appointed Dr. Stephen J. Piercey, FGC to its Technical & Advisory Board. Dr. Piercey's recognized expertise in volcanogenic massive sulphide (VMS) mineralization—particularly within the Newfoundland Appalachians—will be a significant asset to Canstar's expanding exploration programs and its recently announced $11.5 million strategic joint venture with VMS Mining Corporation (VMSC). Dr. Piercey will support Canstar's technical team as the Company advances its exploration efforts in partnership with VMSC. The recently launched JV targets underexplored areas within the Buchans-Mary March VMS corridor, an area that has yielded some of the highest-grade polymetallic mineralization globally. This appointment further strengthens Canstar's technical capabilities and underscores its dedication to data-driven, scientifically rigorous exploration in one of Canada's most prolific but underexplored VMS districts. 'We are thrilled to welcome Dr. Piercey to our team at a pivotal time in the Company's evolution,' said Juan Carlos Giron Jr., President & CEO of Canstar. 'His deep understanding of VMS deposits, including those of the Newfoundland Appalachians makes him an ideal technical advisor as we execute on our exploration strategy in Newfoundland. His appointment reflects our commitment to scientific excellence and our focus on technically rigorous exploration.' Alignment with Canstar's Strategic Objectives Canstar's ongoing exploration focus in Newfoundland—including the recently announced VMSC JV—aligns closely with Dr. Piercey's area of specialization. His appointment brings several immediate benefits: About Dr. Stephen Piercey Dr. Piercey is a University Research Professor and Full Professor in the Department of Earth Sciences at Memorial University of Newfoundland (MUN), where he leads the Piercey Research Group and a consulting geologist with Piercey Geosciences Inc.. An expert in economic geology, he specializes in lithostratigraphy, volcanology, hydrothermal alteration, and geochemistry—applying integrated field, petrographic, lithogeochemical and microanalytical techniques to understanding VMS, orogenic gold, uranium, and other base-metal systems. A Memorial University alumnus (BSc(Hons), MSc), he holds a PhD from UBC and is recognized as a Fellow of Geoscientists Canada (FGC), recipient of the distinguished Duncan R. Derry Medal from the Mineral Deposits Division of the Geological Assocation of Canada, and recipient of Memorial's University Research Professor award. He is a Professional Geoscientist (PGeo) in Newfoundland and Labrador, Ontario, and British Columbia. Dr. Piercey has secured over $9 million in research funding, published extensively (100+ peer-reviewed papers, government reports, technical guides), supervised more than 50 graduate students and post-docs, and previously served as the NSERC-Altius Industrial Research Chair in Mineral Deposits. His groundbreaking work on Newfoundland's Cambrian-Ordovician VMS systems—such as Duck Pond, Sail Pond, Ming, and projects in the Buchans-Roberts Arm Belt—advances Canstar's scientific understanding and exploration tools in the region. Additional Information on Canstar's Buchans and Mary March Projects Canstar's Buchans and Mary March Projects are located in the Buchans-Roberts Arms Belt of west-central Newfoundland, Canada. Recognized as one of the highest-grade VMS systems in history, Buchans was mined by ASARCO from the 1920s to the 1980s. Five deposits yielded 16.2 million tonnes with average mill head grades of 14.51% zinc, 7.56% lead, 1.33% copper, 122 g/t silver, and 1.37 g/t gold. 2 Canstar's Buchans Project sits immediately adjacent to the historic Buchans mines. New 3D geological modelling (2024) by Canstar indicates that the Buchans River Formation, the geological host unit for all five historic Buchans Mine deposits, underlies Canstar's entire Buchans property at depth. The formation plunges from the historically mined deposits towards Canstar's adjacent Buchans-area claims. A SkyTEM time-domain electromagnetic survey in 2017 identified several multi-kilometre geophysical anomalies within Canstar's Buchans claims. The anomalism coincides with an area of low magnetism, indicating a potential alteration zone. A historic drillhole from the 1970s—located within one of these anomalies—intersected what was described as 'stockwork style' mineralization. Stockwork zones typically exhibit a geophysical signature characterized by low magnetism, variable (generally poor to moderate) electrical conductivity, and good chargeability. These characteristics are similar to the geophysical attributes of the stockwork zones of the historic Buchans deposits, suggesting the potential discovery of stockwork and alteration zones associated with Buchans-style VMS deposits. Canstar's Mary March project, located 25km from the historic Buchans mines, features a large mineralized system with alteration zones similar in scale to those at Buchans and high-grade massive sulphides. Historic drilling intersected a faulted-off massive sulphide lens 9.63 m thick, assaying 0.64% Cu, 1.8% Pb, 10.1% Zn, 4.2 g/t Au, 122 g/t Ag. 1 In 2019, Canstar trenching identified Buchans-style debris flow deposits with massive sulphide clasts, which assayed up to 5.7% Cu, 1.6% Pb, 1.8% Zn, 29.4 g/t Ag, and 1.2 g/t Au. 2 Other Corporate Updates On June 16, 2025, Canstar's Board of Directors approved the grant of an aggregate of 1,110,000 incentive stock options (the 'Options') to officers, directors, consultants, and employees of the Company pursuant to its stock option plan. The Options are exercisable at a price of $0.05 per common share and will expire on June 16, 2030. The Options are subject to specific vesting provisions as determined by the Board of Directors and in accordance with the policies of the TSX Venture Exchange (the 'Exchange'). Footnotes (1) Reported by Phelps Dodge in 1999 (historic unverified assays): 9.63 metres grading 4.2 g/t gold, 122 g/t silver, 10.1% zinc, 1.8% lead, and 0.64% copper (2) Historical production source: Zinc and Lead, Mineral Commodities of Newfoundland and Labrador, Geological Survey of Newfoundland and Labrador, Compiled by R.J. Wardle, 2008 Qualified Person Statement Bob Patey (Hons), Vice President for Exploration for Canstar and a Qualified Person as defined in NI 43-101, has prepared and approved all scientific and technical information disclosed in this news release. Acknowledgement Canstar acknowledges the financial support of the Junior Exploration Assistance (JEA) Program from the Government of Newfoundland and Labrador Department of Industry, Energy and Technology, which has been a valuable contribution to the exploration programs on the Company's Buchans-Mary March and Golden Baie projects. About Canstar Resources Inc. Canstar Resources Inc. (TSXV: ROX) is an exploration company focused on critical minerals and gold. The Company's 100%-owned Golden Baie Project (489.5 km²) hosts high-grade gold and antimony showings along a major mineralized structure that also hosts a large number of gold deposits. The Buchans and Mary March projects (120.5 km 2 ) are located within the past-producing VMS zinc-, copper-, and silver-rich Buchans Mining Camp and boast high-grade zinc and copper discoveries. For further information, please contact: Juan Carlos Giron, Jr. President & Chief Executive Officer Email: [email protected] Phone: (647) 557-3442 Website: Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release includes certain 'forward-looking statements' that are not comprised of historical facts. Forward-looking statements include estimates and statements that describe the Company's plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as 'believes,' 'anticipates,' 'expects,' 'estimates,' 'may,' 'could,' 'would,' 'will,' or 'plan.' Since forward-looking statements are based on assumptions and address future events and conditions, they involve inherent risks and uncertainties. Although these statements are based on information currently available to the Company, the Company does not assure that actual results will meet management's expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward-looking information in this news release includes, but is not limited to: the execution and terms of the proposed partnership with TerraAI, the anticipated benefits of AI deployment in mineral exploration, the objectives and scope of the $11.5 million joint venture with VMS Mining Corporation, the expectation that the use of AI can improve discovery probabilities and reduce costs, exploration plans for the Buchans and Mary March projects, and any future drilling or data interpretation outcomes. Forward-looking information also includes the Company's business objectives, exploration results, potential mineralization, the estimation of mineral resources, timing of exploration and development plans, and assumptions about market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to: the risk that the definitive agreement with TerraAI is not completed; the technology does not perform as anticipated; AI integration does not result in discovery success or cost efficiencies; difficulties accessing or validating historical data; limitations in data modeling or interpretation; delays or disruptions to the current Deep IP survey; and risks generally associated with the adoption of novel technologies in exploration. Additional risks include failure to identify mineral resources, failure to convert estimated mineral resources to reserves, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate First Nations and other indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects capital and operating variances. and those risks set out in the Company's public documents filed on SEDAR+. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release. No assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. To view the source version of this press release, please visit
Time of India
6 days ago
- Business
- Time of India
Get real-time updates as GCC adds more digital boards
Chennai: To boost real-time public communication and reinforce its smart city infrastructure, the Greater Chennai Corporation (GCC) will install 100 additional Variable Messaging Displays (VMDs) across the city. These digital boards will provide live updates on traffic, emergency alerts, and civic information. The new VMDs will be set up in high-footfall areas, including parks, beaches, playgrounds, and govt buildings. Operated daily from 7am to 10pm, each unit will have dedicated time slots during peak hours for public interest messages such as weather warnings, health campaigns, and disaster alerts. A senior GCC official said a feasibility study will be carried out to identify optimal locations based on visibility, foot traffic, and communication effectiveness. The expansion follows a Public-Private Partnership (PPP) model, with commercial advertisements shown during non-critical hours. The System Integrator (SI), tasked with installation and maintenance, will manage ad slots and recover costs through ad revenue. "The 97 existing VMDs demonstrated both public utility and commercial viability. Between Sept 2024 and March 2025, the SI generated about 15 crore in ad revenue. With the new rollout, we expect an additional 12 crore annually," the official said. An earlier initiative to track real-time ambulance movement on VMS boards at 16 major junctions, including Poonamallee High Road, remains operational. However, the proposed expansion to 40 locations has not yet materialised. To support the rollout, GCC allocated 6 crore in the 2025–2026 budget. This includes infrastructure costs such as electricity connections and cabling, estimated at 85,000 per unit. Annual power costs are projected at 1.44 lakh per VMD.
Yahoo
10-06-2025
- Business
- Yahoo
Alpha Vision to Attend Apartmentalize 2025, Showcasing Integrated Security Solutions for Multifamily Housing
SUNYVALE, Calif., June 10, 2025 /PRNewswire/ -- Alpha Vision, a leader in AI-driven security technology, announced that it will be attending Apartmentalize 2025, the National Apartment Association's flagship conference for the multifamily housing industry. The event, taking place June 11–13, 2025 at the Las Vegas Convention Center, is expected to draw over 12,000 apartment housing professionals from across the country. As the rental housing industry's ultimate annual gathering, Apartmentalize features world-class speakers, educational sessions, and an expo showcasing the latest products and services for apartment management. At this dynamic forum, Alpha Vision will be demonstrating its integrated security solutions designed to help apartment managers tackle core operational and security pain points, from protecting properties against theft and vandalism to streamlining incident response. Addressing Security Challenges in Multifamily Communities Apartment communities face a range of security challenges that impact both residents and management. Recent surveys show that package theft, car break-ins, and unauthorized visitors are among the most frequent problems reported by residents. In fact, 71% of U.S. apartment renters believe property managers should do more to improve security on their properties. Property managers not only have to safeguard their communities against these threats, but they also contend with operational pressures like coordinating multiple security systems, handling after-hours incidents, and mitigating liability for on-site crimes. Alpha Vision's presence at Apartmentalize underscores the growing importance of smarter security in the multifamily sector and the company's commitment to delivering solutions that directly address these pain points. "Security is top-of-mind for today's apartment managers because it's top-of-mind for their residents," said Yi Jin, Head of Marketing at Alpha Vision. "At Alpha Vision, we are committed to continuous innovation that makes properties safer and managers' jobs easier. By integrating cutting-edge hardware, intelligent software, and live monitoring into one platform, we deliver unparalleled value – reducing incidents, response times, and costs for apartment communities. We look forward to showing Apartmentalize attendees how our technology can solve their toughest security challenges while improving peace of mind for everyone on-site." End-to-End Security Solutions for Apartment Managers At Apartmentalize 2025, Alpha Vision will showcase its comprehensive security platform that combines plug-and-play hardware, an AI-powered Video Management System (VMS), and 24/7 professional monitoring. This unified approach allows property management professionals to protect residential communities end-to-end with a single vendor solution. Alpha Vision's ecosystem addresses everything from proactive threat detection to real-time incident response and post-event case reporting, eliminating the need for disjointed systems or costly on-site guards. Attendees at the conference can expect to see live demonstrations of how Alpha Vision's technology works in a residential setting. The company's team will illustrate common scenarios – for example, how AI-driven cameras automatically detect and deter an unauthorized person in a parking lot at night, or how a remote monitoring center can intervene with a voice warning and dispatch authorities in real time. By consolidating hardware, software, and services, Alpha Vision's solution not only improves security outcomes but also simplifies day-to-day operations for apartment staff. Key Features of Alpha Vision's Platform Plug-and-Play Hardware with Long-Range Night Vision: Enterprise-grade security cameras and sensors designed for apartment environments – from parking lots to hallways – offering crystal-clear video quality even in low-light conditions. With long-range infrared night vision, all devices come pre-configured for rapid, disruption-free deployment. AI-Powered Autonomous Patrols: Built-in AI acts as a virtual security guard, controlling pan-tilt-zoom cameras to autonomously patrol premises 24/7, detect unusual activities, and instantly flag suspicious behavior. Real-Time Alerts and Intelligent Analytics: Smart alerts for loitering, intrusions, or unexpected activity, delivered instantly to property staff and monitoring teams. Smart analytics minimize false alarms for faster, smarter responses. Seamless VMS Integration: Cloud-based video management software consolidates live and recorded feeds in a single dashboard. Compatible with existing systems and offers powerful search tools like natural-language or object-based video retrieval. 24/7 Remote Live Monitoring: Professionally staffed security teams watch live feeds and respond to alerts during off-hours or at scale. Virtual guard coverage reduces the need for on-site staff and improves after-hours protection. Domestic Dispatch and Intervention: U.S.-based dispatchers coordinate with local police or on-site security, delivering live voice-down deterrents and emergency coordination in real time. Comprehensive Case Management: All incidents are logged into the platform automatically, producing time-stamped video reports and summaries that streamline liability reviews and follow-ups. Connecting with the Industry and Creating Opportunities at Apartmentalize 2025 Apartmentalize 2025 represents a key moment for Alpha Vision to engage with the broader multifamily housing community and foster meaningful partnerships across the industry. More than just a product showcase, Alpha Vision sees this event as a platform to exchange insights, collaborate with peers, and uncover new ways technology can elevate residential property management. The Alpha Vision team looks forward to connecting with property owners, management firms, technology integrators, and industry leaders who are seeking innovative, scalable security solutions. By participating in hands-on conversations and listening to the unique challenges faced by different operators, Alpha Vision aims to create tailored strategies that deliver real value to every community. At the exhibition booth, attendees can expect: Live interactive demonstrations showcasing AI patrols, smart alerts, and video search in action One-on-one consultations with product specialists to discuss site-specific needs Engaging opportunities like giveaways, free on-site security assessments, and demo scheduling incentives "Apartmentalize gives us a powerful opportunity to connect with the people shaping the future of residential living," said Yi Jin, Head of Marketing at Alpha Vision. "We're excited to explore new partnerships, learn from our peers, and demonstrate how our technology can empower apartment communities to operate safer, smarter, and more efficiently." Join Alpha Vision at Apartmentalize 2025 Apartmentalize 2025 will be held at the Las Vegas Convention Center – West Hall (300 Convention Center Dr., Las Vegas) from June 11 to 13. Alpha Vision will be exhibiting throughout the event and invites attendees to explore its cutting-edge platform at Booth #882. The Alpha Vision team will be available for live demonstrations, including real-time video search, AI patrols, and dispatch simulations. Private demo bookings and follow-up consultations can be scheduled during or after the event. About Alpha Vision Alpha Vision is a leading provider of next-generation AI-powered physical security solutions. The company's flagship platform harnesses artificial intelligence and video analytics to help organizations proactively monitor and protect their premises, reducing incidents and improving response times. Alpha Vision's product suite is used in retail, commercial, and industrial settings worldwide to transform standard surveillance cameras into smart, preventive security systems. With the launch of the Alpha Vision Shop, the company expands its offerings to deliver high-quality security hardware alongside its innovative software, reaffirming its commitment to safety, innovation, and customer service in the surveillance industry. Media Contact: Yi Jin, of Marketing, Alpha VisionEmail: yi@ View original content to download multimedia: SOURCE Alpha Vision Sign in to access your portfolio
The Hindu
02-06-2025
- Automotive
- The Hindu
Variable message system comes up at Red Cross junction roundabout in Coimbatore
A variable message system (VMS) that has been installed at the Red Cross junction roundabout will create awareness among the public on social issues and road safety. Coimbatore District Collector Pavankumar G. Giriyappanavar inaugurated the new arrangement in the presence of Corporation Commissioner M. Sivaguru Prabhakaran, Deputy Commissioner of Police (Traffic) S. Ashok Kumar and G. Manuneethi, Divisional Engineer (Road Safety) for Coimbatore Circle. The VMS consists of a large LED board mounted on an aesthetically designed metal structure. The LED board will display awareness messages on road safety, drug abuse, traffic violations, crimes against children and women, child labour and other social issues. C. Palanivelu, Chairman of GEM Hospital and Research Centre, sponsored the VMS while JS Associate Development (I) Pvt Ltd supported the installation, said the police. According to Mr. Ashok Kumar, the VMS will not display motion contents as they might divert the attention of motorists. The system will only display awareness contents as still images. He said that more such arrangements could be installed across the city if sponsors supported with corporate social responsibility funds.
Business Wire
02-06-2025
- Health
- Business Wire
Elinzanetant Significantly Reduces Frequency of Moderate to Severe Vasomotor Symptoms Associated With Endocrine Therapy for Breast Cancer in Phase III Oasis-4 Study
BERLIN--(BUSINESS WIRE)--Detailed results from the Phase III OASIS-4 study found that the investigational compound elinzanetant showed a statistically significant reduction in the frequency of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) from baseline to weeks 4 and 12 compared to placebo, in women taking endocrine therapy for treatment or prevention of hormone receptor (HR+) breast cancer. Key secondary endpoints showed statistically significant improvement of sleep disturbances and menopause-related quality of life from baseline to week 12 versus placebo. Additional secondary endpoints showed a reduction in VMS frequency at week 1 and improvements in VMS severity at weeks 4 and 12 versus placebo. These data are being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 – June 3 in Chicago, IL, USA, and have been simultaneously published in the New England Journal of Medicine (NEJM). OASIS-4 is the first pivotal international Phase III study to assess the safety and efficacy of elinzanetant for the treatment of moderate to severe VMS associated with endocrine therapy for the treatment or prevention of HR+ breast cancer. 'Menopausal symptoms are frequent side effects of endocrine therapy for breast cancer, often leading to discontinuation, which is why management of these symptoms can play an important role in breast cancer treatment,' said Dr. Fatima Cardoso, Principal Investigator of OASIS-4, from Lisbon Portugal. 'With no currently approved treatments for this indication, there is an unmet medical need for therapeutic options.' In OASIS-4, elinzanetant showed statistically significant mean reductions in frequency of VMS compared to placebo from baseline to week 4 with −6.5 (95% confidence interval [CI], −7.2 to −5.8) with elinzanetant and −3.0 (95% CI, −3.9 to −2.2) with placebo, with statistical significance between elinzanetant and placebo (least squares [LS] mean difference [95% CI]: −3.5 [−4.4, −2.6]; p<0.001). At week 12, reductions in VMS frequency were −7.8 (95% CI, −8.5 to −7.1) with elinzanetant and −4.2 (95% CI, −5.2 to −3.2) with placebo, with statistical significance between elinzanetant and placebo (LS mean difference [95% CI]: −3.4 [−4.2, −2.5]; p<0.001). The safety profile over 52 weeks observed in the OASIS-4 study is generally consistent with previously conducted studies and published data 1,2,3 on elinzanetant in postmenopausal women with VMS, with fatigue, somnolence and diarrhea being the most frequent treatment emergent adverse events (TEAEs) in the elinzanetant group. The mean change in the PROMIS SD SF 8b total T score from baseline to week 12 was −10.6 points (95% CI, −11.5 to −9.6) in the elinzanetant group and −4.1 points (95% CI, −5.3 to −2.9) in the placebo (LS mean difference between the trial groups, −6.1 points; 95% CI, −7.5 to −4.8; p<0.001). The mean change in the MENQOL total score from baseline to week 12 was −1.3 points (95% CI, −1.4 to −1.2) in the elinzanetant group and −0.5 points (95% CI, −0.7 to −0.3) in the placebo group (LS mean difference between the trial groups, −0.7 points; 95% CI, −0.9 to −0.5; p<0.001). Additional secondary endpoints showed a reduction in VMS frequency at week 1 and in VMS severity at weeks 4 and 12 with elinzanetant versus placebo. 'The results from OASIS-4 represent a potential advancement in addressing a need for women undergoing breast cancer treatment. Vasomotor symptoms associated with endocrine therapy can impact patients' quality of life and may impact their ability to adhere to other treatments,' said Dr. Christian Rommel, member of the Executive Committee of Bayer AG's Pharmaceutical Division and Global Head of Research and Development. 'Advancing elinzanetant as an investigational, hormone-free treatment option for these patients reaffirms our commitment at Bayer to bring forward innovative treatments for the different health needs of women.' Breast cancer is the most commonly diagnosed cancer in women globally with 2.3 million new cases in 2020, and nearly 70% of tumors being hormone-receptor positive. Adjuvant endocrine therapy is well established in guidelines worldwide and routinely prescribed to all women with hormone-positive breast cancer. Treatment with adjuvant endocrine therapy (such as tamoxifen) for up to 10 years substantially reduces the breast cancer mortality rate throughout the two decades after diagnosis. 4 Endocrine therapy can also be used as primary prevention, in women at high risk of developing breast cancer. Side effects of endocrine therapy, such as VMS (also referred to as hot flashes), may affect quality of life and treatment compliance, with potential impact on recurrence. 5 Currently, there are no approved treatment options available. There is an unmet medical need for an effective hormone-free treatment for VMS associated with endocrine therapy. Elinzanetant is the first dual neurokinin targeted therapy, antagonizing NK-1 and NK-3 receptors, in late-stage clinical development globally for the treatment of moderate to severe VMS due to menopause or associated with endocrine therapy for breast cancer, administered orally once daily. Data from OASIS-1 and -2 were published in the Journal of the American Medical Association (JAMA) 3 in August 2024. Detailed results of the Phase III study OASIS-3 providing additional efficacy and safety data over 52 weeks were presented at The Menopause Society (TMS) annual meeting in September 2024. Based on the positive results from the Phase III clinical development program, submissions for marketing authorizations for elinzanetant are ongoing in the US, EU and other markets around the world. About the Elinzanetant Clinical Development Program The Phase III clinical development program of elinzanetant, OASIS, currently comprises four Phase III studies: OASIS-1, -2, -3 and -4. OASIS-1 and -2 investigated the efficacy and safety of elinzanetant administered orally once daily in women with moderate to severe VMS associated with menopause over 26 weeks and randomized 396 and 400 postmenopausal women between 40 and 65 years across 184 sites in 15 countries. Patients in the elinzanetant arm received a 120 mg dose of elinzanetant once daily for 26 weeks and patients in the control arm received a matching placebo once daily for 12 weeks, followed by elinzanetant 120 mg dose for 14 weeks. OASIS-3 investigated the efficacy and safety of elinzanetant for the treatment of VMS due to menopause over 52 weeks and randomized 628 postmenopausal women between 40 and 65 years across 83 sites in 9 countries. OASIS-4 is a double-blind, randomized, placebo-controlled multicenter study to investigate the efficacy and safety of elinzanetant for the treatment of VMS associated with endocrine therapy for treatment or prevention of HR+ breast cancer over 52 weeks and optionally for an additional 2 years in women taking endocrine therapy, for treatment of breast cancer. 474 patients at 90 centers in 16 countries (excluding the US) were randomized. About Elinzanetant Elinzanetant is the first dual neurokinin targeted therapy, antagonizing NK-1 and NK-3 receptors, in late-stage clinical development globally for the treatment of moderate to severe VMS due to menopause or associated with endocrine therapy for breast cancer, administered orally once daily. Elinzanetant may address moderate to severe VMS by modulating a group of estrogen sensitive neurons in the hypothalamus region of the brain (the KNDy neurons) which, with the decrease of estrogen, become hypertrophic and lead to a hyperactivation of the thermoregulatory pathway, consequently disrupting body heat control mechanisms resulting in VMS. About Vasomotor Symptoms Vasomotor symptoms (VMS; also referred to as hot flashes) result from hyperactivation of the thermoregulatory pathway mediated by hypertrophy of the KNDy neurons. This is due to a decrease of estrogen, which can result from the progressive reduction of ovarian function due to natural menopause or medical intervention by bilateral oophorectomy or endocrine therapy. VMS are reported by up to 80% of women at some point during the menopausal transition and are one of the leading causes for seeking medical attention during this phase of a woman's life. Over one-third of menopausal women report severe symptoms, which can last 10 years or more after the last menstrual period, with relevant impact on quality of life. VMS may also be caused by endocrine therapy, for the treatment or prevention of breast cancer, impacting quality of life and treatment adherence. For these women, there are currently no approved treatment options. About Menopause By 2030, the global population of women experiencing menopause is projected to increase to 1.2 billion, with 47 million women entering this phase each year. Menopause is a transitional phase in women's lives, related to the progressive decline of ovarian function. It usually occurs in women during their 40s or early 50s. It can also be the result of surgical or medical treatment, such as breast cancer treatment. The hormonal decline can lead to various symptoms which can substantially affect a woman's health, quality of life, healthcare utilization and work productivity. The most frequently reported and disruptive symptoms during the menopausal transition are VMS, sleep disturbances and mood changes. Addressing these symptoms is key to maintaining functional ability and quality of life in menopause, which is highly relevant from both a healthcare and socio-economic perspective. About Women's Healthcare at Bayer Women's Health is in Bayer's DNA. As a global leader in women's healthcare, Bayer has a long-standing commitment to delivering science for a better life by advancing a portfolio of innovative treatments. Bayer offers a wide range of effective short- and long-acting birth control methods as well as therapies for menopause management and gynecological diseases. Bayer is also focusing on innovative options to address the unmet medical needs of women worldwide and to broadening treatment choices such as in menopause. Additionally, Bayer intends to provide 100 million women per year in low-and-middle income countries by 2030 with access to family planning by funding multi-stakeholder aid programs for capacity building and by ensuring the supply of affordable modern contraceptives. This is part of the comprehensive sustainability measures and commitments from 2020 onwards and in line with the Sustainable Development Goals of the United Nations. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, 'Health for all, Hunger for none,' the company's products and services are designed to help people, and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to Find more information at Follow us on Facebook: Follow us on LinkedIn: Bayer | Pharmaceuticals kw (2025-0077E) Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. References Simon JA, Anderson RA, Ballantyne E, Bolognese J, Caetano C, Joffe H, Kerr M, Panay N, Seitz C, Seymore S, Trower M, Zuurman L, Pawsey S. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). Menopause. 2023 Mar 1;30(3):239-246. Trower M, et al. Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial. Menopause: The Journal of The North American Menopause Society. 2020; 27 (5): 498-505. Davies C, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. The Lancet. 2013 Mar 9;381(9869):805-16. Smith, K.L., Verma, N., Blackford, A.L. et al. Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation. npj Breast Cancer 8, 53 (2022). Expand
